Last reviewed · How we verify
NCT07062744
The Role of Swan-Ganz Catheter in Hemodynamic Resuscitation for Patients With Cardiogenic Shock
NA trial testing Swan-Ganz IQ Pulmonary Arterial catheter in Cardiogenic Shock in 108 participants. Currently enrolling.
1 December 2027
Quick facts
| Lead sponsor | Bach Mai Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 108 |
| Start date | 27 May 2025 |
| Primary completion | 1 December 2027 |
| Estimated completion | 30 December 2027 |
| Sites | 1 location across Vietnam |
Drugs / interventions tested
- Swan-Ganz IQ Pulmonary Arterial catheter
- Swan-Ganz IQ catheter
Conditions studied
- Cardiogenic Shock — all drugs for Cardiogenic Shock →
- Pulmonary Artery Catheter Waveform Interpretation — all drugs for Pulmonary Artery Catheter Waveform Interpretation →
- Hemodynamic Management — all drugs for Hemodynamic Management →
- Hemodynamic Optimization — all drugs for Hemodynamic Optimization →
Sponsor
Bach Mai Hospital
Who can join
18 and older, any sex, with Cardiogenic Shock or Pulmonary Artery Catheter Waveform Interpretation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial examines whether the use of the Swan-Ganz catheter, a specialized pulmonary artery catheter, can improve hemodynamic management and treatment outcomes in patients experiencing cardiogenic shock due to acute myocardial infarction (AMI). Cardiogenic shock is a critical condition marked by the heart's inability to supply adequate blood to the organs, often resulting from a severe heart attack. Despite advancements in care, the condition remains associated with high mortality. Effective monitoring of cardiovascular status is crucial in guiding timely and tailored treatment decisions. Participants in this study will undergo advanced hemodynamic monitoring using the Swan-Ganz catheter, which provides continuous data on cardiac output and other key parameters. This information enables physicians to better assess circulatory function and adjust therapies accordingly. The research will evaluate clinical characteristics, response to treatment, and 30-day outcomes in patients managed with this technique. The study also aims to identify factors associated with successful hemodynamic stabilization and potential complications related to catheter use. A total of 108 adult patients meeting specific eligibility criteria will be enrolled at Bach Mai Hospital over 3 years. Participation is voluntary, and all patients will continue to receive standard-of-care treatment. All personal and medical data will be handled with strict confidentiality.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07062744
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiogenic Shock
Currently open trials in the same condition.
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07345559 — Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock · NA · recruiting
- NCT07374289 — On Scene ECPR in Ostrava · NA · recruiting
- NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
- NCT07309029 — Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR · recruiting
Other Bach Mai Hospital trials
Trials by the same sponsor.
- NCT07462195 — Dexmedetomidine for Improving Emergence Quality in Thyroid Surgery · Phase 4 · recruiting
- NCT07516795 — Analgesic Efficacy of Continuous S-ESP vs Continuous FICB After Hip Arthroplasty · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07062744 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bach Mai Hospital
- Last refreshed: 14 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07062744.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing